East Windsor, NJ — Sabinsa Corporation’s shelf-stable probiotic LactoSpore was recently granted a U.S. patent approving the use of Lactospore (Bacillus coagulans MTCC 5856) as a therapy for the management of Irritable Bowel Syndrome (IBS).
A Product License was issued to Sabinsa for its Lactospore product by Health Canada, the federal organization that assists the residents of Canada in pursuing a healthy lifestyle, in 2016. Health Canada found that Lactospore Balance “helps relieve abdominal pain associated with IBS (Irritable Bowel Syndrome).”
“Sabinsa’s 136 patents demonstrate the continuous innovation process that Sabinsa proudly brings to its ingredients portfolio,” Sabinsa Marketing Director Shaheen Majeed said in a statement.
The Patent No. US9579352 claims that when used as a dietary supplement in conjunction with regular treatment, administering a formulation comprised of Bacillus coagulans MTCC 5856 (not less than 2 billion spores) can manage symptoms of IBS such as abdominal pain and distension, constipation and loose stools. A recently published study using a human clinical trial, (Majeed et al. Nutrition Journal (2016) 15:21 DOI 10.1186/s12937-016-0140-6), indicated that Lactospore alleviates clinical symptoms of IBS in patients suffering from the disease.